Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-10-053927
Filing Date
2010-03-11
Accepted
2010-03-11 16:44:56
Documents
7
Period of Report
2009-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K d10k.htm 10-K 1393648
2 BUPROPION HYDROCHLORIDE SUPPLY AGREEMENT dex1023.htm EX-10.23 207089
3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM dex231.htm EX-23.1 2358
4 CERTIFICATION OF CHIEF EXECUTIVE OFFICER dex311.htm EX-31.1 8472
5 CERTIFICATION OF CHIEF FINANCIAL OFFICER dex312.htm EX-31.2 8471
6 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER dex321.htm EX-32.1 8172
7 GRAPHIC g30527g09h10.jpg GRAPHIC 49805
  Complete submission text file 0001193125-10-053927.txt   1698423
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Filer) CIK: 0001382911 (see all company filings)

EIN.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-33415 | Film No.: 10674507
SIC: 2834 Pharmaceutical Preparations